NCT06915584
Drug Management in Heart Failure
Recruiting · Not specified · IRCCS San Raffaele Roma · registry updated 2026-10-20
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Aim of the proposal is to create an interactive AI-based multicentre prospective database to provide information on how to improve the QoC for pts with HF.This will provide detailed information on pts characteristics,treatment practices, adherence to prescribed guideline-based optimal drug therapy,and outcomes.The database stems from a registry started two years ago,conceived to provide a contemporary snapshot on the adherence to the latest European GGLL for the therapeutic management of pts with HF.The database will be integrated with a specifically designed algorithm that provides an accurate feedback on whether patients are properly treated according to the ESC most recent recommendations.The expected outcomes are:-define non-adherence level to GGLL-based recommendations for treatment of HF;-provide information on initiation, adherence and persistence over time of the recommended treatment;-reduce medical inertia;produce practical implications to reduce morbidity and mortality
Inclusion
- Age \>18 years
- Signed informed consent for the study
- Known diagnosis of heart failure \> 6 months
- Recent or ongoing hospitalization for heart failure exacerbation
Exclusion
- Conditions that, in the investigator's judgment, may interfere with the study or contraindicate participation for safety reasons
- Concurrent diagnosis of neoplasia
- Advanced COPD (FEV1 \<50%)
- Advanced valvular heart disease (severe mitral-aortic stenosis-insufficiency requiring cardiac surgery)